CRPC w/ bone metastases

eRADicAte: A Study of Radium-223 with Abiraterone Acetate in Castration-Resistant Prostate Cancer with Symptomatic Bone Metastases

Details
Neal Shore, MD. presents the eRADicAte study, an open label phase two clinical trial of radium-223 with concurrent administration of abiraterone acetate plus prednisone in castration-resistant prostate cancer (CRPC) subjects with symptomatic bone metastases without visceral metastases. These results were first presented at the AUA 2016. Potential synergy exists in combining radium-223 and abirater...

Detection of Metastatic Disease in Prostate Cancer: Past, Present, Future

Details
Detection of Metastatic Disease in Prostate Cancer: Past, Present, Future Phillip Koo, MD Associate Professor, Radiology - Nuclear Medicine University of Colorado School of Medicine Aurora, Colorado Dr. Koo is the associate professor of radiology, nuclear medicine at the University of Colorado School of Medicine. He is a graduate of Drexel University College of Medicine and is a Fellow at the Brig...

Radiopharmaceuticals in Prostate Cancer

Details
Stefano Fanti, MD. presents "RADIOPHARMACEUTICALS IN PROSTATE CANCER" from the NCCN and EAU guidelines to the new tracers this state of the art lecture is followed with a Q & A with E. David Crawford, MD. Stefano Fanti, MD. Director of Specialty School of Nuclear Medicine at University of Bologna Nuclear Medicine, Associate Professor, University of Bologna, Director of Nuclear Medicine Division an...

Radium-223: Nuclear Medicine Perspective

Details
Phillip Koo, MD Associate Professor, Radiology - Nuclear Medicine University of Colorado School of Medicine Aurora, Colorado Dr. Koo is the associate professor of radiology, nuclear medicine at the University of Colorado School of Medicine. He is a graduate of Drexel University College of Medicine and is a Fellow at the Brigham and Women's Hospital/Children's Hospital/Harvard Medical School Progra...

mCRPC Treatment: Combination Therapy - Clinical Case

Details
A clincial patient case from Charles Ryan, MD. Professor of Clinical Medicine and Urology, Department of Medicine, UCSF, Program Leader, Genitourinary Medical Oncology, UCSF Thomas Perkins Distinguished Professor in Cancer Research, UCSF Biography: Dr. Ryan is Professor of Clinical Medicine and Urology at the UCSF Helen Diller Family Comprehensive Cancer Center where he is the Clinical Program Lea...

Detection of Metastatic Disease: Review of the RADAR Group Recommendations

Details
Phil Koo, MD. reviews the detection of metastatic catration-resistant prostate cancer disease in a Review of the RADAR Group Recommendations

Radium-223 in an International Early Access Program (EAP): Effects of Concomitant Medication on Overall Survival in Metastatic Castration-Resistant Prostate Cancer (mCRPC)

Details
Radium-223 in an International Early Access Program (EAP): Effects of Concomitant Medication on Overall Survival in Metastatic Castration-Resistant Prostate Cancer (mCRPC). Presented by: Dr. Fred Saad. Professor and Chief of Urology and Director of GU Oncology at the University of Montreal Hospital Centers, in Montreal, Canada. On behalf of my co-authors, it gives me great pleasure to present the...

Effects of concomitant use of abiraterone and/or enzalutamide with radium-223

Details
Thomas Keane, shares recent data presented at the ECC : Effects of concomitant use of abiraterone and/or enzalutamide with radium-223 on safety and overall survival in metastatic castration-resistant prostate cancer (mCRPC) patients treated in an international early access program (EAP) Thomas E. Keane, MBBCh, FRCSI, FACS, is Professor and Chairman of the Department of Urology at the Medical Unive...

Radium-223 For mCRPC: The Urologist Perspective

Details
Radium-223 For Metastatic Castration-resistant Prostate Cancer: The Urologist Perspective - Presented by Neal Shore, MD. Radium-223 dichloride (radium-223) is an important therapeutic option for the treatment of patients with castration-resistant prostate cancer, symptomatic bone metastases, and no visceral disease. The unique mechanism of action of this first-in-class alpha-emitting radiopharmace...

The Art and Science of Treating CRPC with Bone Metastases

Details
The Art and Science of Treating CRPC with bone metastases integrating Radium-223 into treatment - Charles Ryan, MD. presents two patient cases. Charles J. Ryan, MD Professor of Clinical Medicine Division of Hematology / Oncology Helen Diller Family Comprehensive Cancer Center University of California, San Francisco BIOGRAPHY Charles J. Ryan, MD is a Professor of Medicine in the Division of Hematol...